CINF 4 |
| Across the pharma and biotechnology industry, reduced hurdles in lead identification are resulting in the screening of druggable targets with weaker disease hypotheses, which will increase the risk and thus incidence of programs that fail in the intended therapeutic area due to lack of efficacy. Nevertheless, these activities will result in a set of chemical tools with which to probe target function and thereby link the corresponding compounds to new therapeutic utility. What is required is sufficiently high throughput methodologies to make de novo links between specific compounds and disease. We have integrated a set of technologies that provide the means of efficiently associating compounds with potential new therapeutic utility. This is in stark contrast to the unsystematic and serendipitous observations that are classically relied upon to reveal alternative or new drug indications. The promise of these technologies is to expeditiously reduce pipeline gaps within a pharmaceutical industry whose growth is threatened by reduced (and increasingly costly) new product flow. |
|
Drug Reprofiling
8:25 AM-12:10 PM, Sunday, August 19, 2007 BCEC -- 252 A, Oral
Division of Chemical Information |